Close
16/03/2017
​A new class of inhibitors against pain investigated at the ALBA synchrotron
The pharmaceutical company ESTEVE (2,470 people, 916 million Euros income in 2016), the Universitat Autònoma de Barcelona (UAB) and the ALBA Synchrotron joined together to investigate the mechanism of action of new inhibitors against pain developed by the company.

Getting new information about the interactions, active site and mechanism of action of the developed drugs and the therapeutic target may help to the better understanding of the effects of the inhibitors and can provide key information to improve their properties. In that sense, the XALOC ALBA beam line offers a valuable tool for carrying out the corresponding experiments.

As a first step, the research will be carried out at the Protein Production Platform of the UAB to obtain the pure protein complexed with the inhibitors. Secondly, X-ray crystallography studies will be performed at the biolab and in ALBA.

This project is a good example of public-private collaboration that fosters the synergies and relationships between the industrial and academic sectors to advance research and innovation.

More news

13/12/2017 ALBA Synchrotron Works for People’s Health 01/12/2017 NanoPlastics Awarded As Best Business Idea Of The UAB University Research Park 23/11/2017 The Excellence of Natura Bissé Awarded by Forbes Travel Guide 08/11/2017 SENER, 50 Years in Space and Ambitious Projects Such As the E-ELT Telescope 02/11/2017 The Barcelona Synchrotron Park in the SmartReFlex European project 26/10/2017 New Findings on Malaria Thanks to ALBA Synchrotron
13 14 15 16 17 18 19 20 21 22 23